US Patent

US10857137 — Methods for the administration of certain VMAT2 inhibitors

Method of Use · Assigned to Neurocrine Biosciences Inc · Expires 2037-10-10 · 11y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects methods of administering valbenazine toosylate to patients who are poor metabolizers of CYP2D6.

USPTO Abstract

Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is a CYP2D6 poor metabolizer.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1995 — valbenazine-tosylate
U-1995 — valbenazine-tosylate
U-1995 — valbenazine-tosylate
U-1995 — valbenazine-tosylate
U-1995 — valbenazine-tosylate
U-1995 — valbenazine-tosylate

Patent Metadata

Patent number
US10857137
Jurisdiction
US
Classification
Method of Use
Expires
2037-10-10
Drug substance claim
No
Drug product claim
No
Assignee
Neurocrine Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.